| Business Summary | | Spectral
Diagnostics
Inc.,
with
locations
in
Canada,
the
United
States
and
Europe,
is
engaged
in
the
development,
manufacturing
and
commercialization
of
its
Cardiac
STATus
line
of
diagnostic
panel
tests,
including
the
patented
Cardiac
Panel.
Spectral's
products
focus
on
decision
point
information
that
is
in
a
format
accessible
to
chest
pain
patient
locations
throughout
the
healthcare
system.
Its
products
are
designed
to
assist
healthcare
professionals
in
making
accurate,
timely
decisions
on
the
earliest
initiation
of
life-saving
treatments
to
the
prevention
of
unnecessary
hospital
stays
with
rapid
and
effective
risk
assessment. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Spectral
Diagnostics
is
a
research
and
product
development
company
focused
primarily
on
its
systems
approach
to
cardiac
diagnostics
that
includes
its
Cardiac
STATus
line
of
cardiac
diagnostics
panel
tests.
For
the
fiscal
year
ended
3/31/01,
revenues
rose
12%
to
C$11
million.
Net
loss
fell
29%
to
C$5.4
million.
Revenues
reflect
increased
Cardiac
STATus
product
sales.
Lower
loss
reflects
decreased
sales
and
marketing
and
amortization
expenses. Recent Earnings Announcement For
the
3
months
ended
06/30/2001,
revenues
were
5,246;
after
tax
earnings
were
1,429. (Preliminary; reported in thousands of Canadian Dollars.) | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | Douglas Ball | Chairman,
CEO | Christopher Plaxton | Exec.
VP, Director | Rose Papastamos | VP-Fin. | Donna Edmonds | VP
of Sales and Marketing | Joseph Keffer | VP,
CMO |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|